{
    "organizations": [],
    "uuid": "4595728e1eb40e2e7a03ad84a0bd224d1c421be9",
    "author": "",
    "url": "https://www.reuters.com/article/brief-biocartis-and-amgen-sign-new-agree/brief-biocartis-and-amgen-sign-new-agreement-idUSFWN1P400R",
    "ord_in_thread": 0,
    "title": "BRIEF-Biocartis And Amgen Sign New Agreement",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 9 (Reuters) - Biocartis Group Nv:\n* REG-BIOCARTIS GROUP NV: BIOCARTIS AND AMGEN SIGN NEW COMPANION DIAGNOSTIC AGREEMENT FOR NOVEL ONCOLOGY COMPOUND\n* AGREEMENT AIMED AT DEVELOPMENT OF IDYLLA(TM) CDX BIOMARKER TESTS\n* FINANCIAL DETAILS ON NEW CDX AGREEMENT WITH AMGEN ARE NOT DISCLOSED. Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-09T08:15:00.000+02:00",
    "crawled": "2018-01-09T09:42:45.288+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "biocartis",
        "group",
        "nv",
        "group",
        "nv",
        "biocartis",
        "amgen",
        "sign",
        "new",
        "companion",
        "diagnostic",
        "agreement",
        "novel",
        "oncology",
        "compound",
        "agreement",
        "aimed",
        "development",
        "idylla",
        "tm",
        "cdx",
        "biomarker",
        "test",
        "financial",
        "detail",
        "new",
        "cdx",
        "agreement",
        "amgen",
        "disclosed",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}